Azacitidine Zentiva 25 mg/ml injektiokuiva-aine, suspensiota varten Suomi - suomi - Fimea (Suomen lääkevirasto)

azacitidine zentiva 25 mg/ml injektiokuiva-aine, suspensiota varten

zentiva k.s. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini

Abacavir Accord 300 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

abacavir accord 300 mg tabletti, kalvopäällysteinen

accord healthcare b.v. - abacavir - tabletti, kalvopäällysteinen - 300 mg - abakaviiri

Kesimpta Euroopan unioni - suomi - EMA (European Medicines Agency)

kesimpta

novartis ireland ltd - ofatumumab - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Enspryng Euroopan unioni - suomi - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressantit - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

FENISTIL-PROLONGATUM 2.5 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

fenistil-prolongatum 2.5 mg depottabletti

novartis consumer health sa - dimetindeni maleas - depottabletti - 2.5 mg - dimetindeeni

Saphnelo Euroopan unioni - suomi - EMA (European Medicines Agency)

saphnelo

astrazeneca ab - anifrolumab - lupus erythematosus, systemaattinen - immunosuppressantit - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Livtencity Euroopan unioni - suomi - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - sytomegalovirusinfektiot - antiviraalit systeemiseen käyttöön - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). on otettava huomioon viralliset ohjeet asianmukaista käyttöä antiviraalisten aineiden.

Opzelura Euroopan unioni - suomi - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Actraphane Euroopan unioni - suomi - EMA (European Medicines Agency)

actraphane

novo nordisk a/s - insulin human - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen hoito.